CA
NZ
UK
AU
IND
US
• Two Distinct Isotope Approaches: Telix uses lutetium-177 (beta emitter) in prostate cancer while Molecular Partners employs lead-212 (alpha emitter) in small cell lung cancer.
• Only Oral Formulation of Levosimendan in Phase 3: If successful, oral levosimendan would be the first oral formulation of an established IV heart failure inotrope to reach approval.
• Eight Companies With Simultaneous Catalysts: A single session produced FDA clearances, clinical data, capital raises, compliance notices, buybacks, reverse splits, patent grants, and biocompatibility results across eight companies.
• The pullback follows a remarkable year-to-date surge of over 144%.
• CLVT shares closed up 16.67% today at $2.59, ranking among the top weekly performers tracked by Morningstar.
• Three Companies Face Compliance Challenges Simultaneously: Mdxhealth received a deficiency notice, NewGenIvf announced a reverse split, and Tenon Medical raised dilutive capital despite positive FDA clearance, all on the same day.
• Strategic IP Milestone: Galmed Pharmaceuticals' (NASDAQ: GLMD) USPTO Notice of Allowance strengthens the company's negotiating position in future licensing talks.
• Non-Negotiable Regulatory Step: Biocompatibility testing under ISO 10993 is a required prerequisite before FDA submission for devices like NASARIX.
• Acceptable Safety Profile Confirmed at ASCO: Phase 3 safety data presented at ASCO demonstrated acceptable safety across all combination cohorts with no new safety signals identified.
• Major Price Target Increase: Chardan Capital raised its EyePoint Pharmaceuticals (NASDAQ: EYPT) target to $65 from $29, a 124% jump, while maintaining a Buy rating.
Please wait processing your request...